|
What is new in the treatment of Waldenstrom macroglobulinemia?
|
|
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia
|
|
Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia
|
|
Long survival in patients with Waldenstrom macroglobulinaemia diagnosed at a young age
|
|
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstrom macroglobulinaemia on ibrutinib
|
|
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstrom macroglobulinaemia
|
|
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
|
|
Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study
|
|
Human MYD88-L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
|
|
How we manage Bing–Neel syndrome
|
|
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia
|
|
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review
|
|
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
|
|
CXCR4-S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenstr¨om macroglobulinemia
|
|
Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events
|
|
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenstr€om Macroglobulinemia
|
|
Bruton’s Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer
|
|
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia
|
|
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
|
|
Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age
|
|
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib
|
|
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
|
|
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
|
|
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia
|
